Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending March 31, 2023
May 06, 2022 at 07:01 am
Share
Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the first half and fiscal year ending March 31, 2023. For the first half, the company expected revenue of JPY 9,500 million, operating profit of JPY 2,450 million, profit attributable to owners of parent of JPY 2,050 million and earnings per share of JPY 49.24.
For the fiscal year, the company expected revenue of JPY 19,600 million, operating profit of JPY 5,000 million, profit attributable to owners of parent of JPY 4,300 million and earnings per share of JPY 103.28.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
